Ahmad Vatani - DMD student Kermanshah University of Medical sciences
Zahra Mirza Asgari - Neurologist Iran University of Medical sciences

Background: Epilepsy is a CNS neurological disorder in which normal brain activity is jammed resulting in seizures or periods of unusual behavior. Untilnow anti-epileptic drugs are only effective inless than one third of epilepticpatients,and predicting biomarkers are not available when the specific antiepileptic drugs treated.Advanced studieshave showed that miRNA may have akeyrollin the pathogenesis of epilepsy. Several target genes and pathways of miRNA which related to the therapeuticmethods to epilepsy.Method: We searched PubMed from Jan 1,2014to Jan 1, 2019using the terms epilepsy ANDmicroRNA AND biomarker and seizure AND microRNA AND biomarker .We selected articlesthat featured novel miRNAs in vivo epilepsy models and patients. Findings: Decrease the expression of has-miR134 could be a potential non-invasive biomarker to usein diagnosis for the epilepsy patients for using hsa-miR-134 also be identified to distinguish patientswithand without epilepsy. miR-181a show significant downregulation in the acute stage, but upregulation in the chronic stage. Other applicable biomarkers for diagnosis of epilepsy are miR-199a,miR124,miR128 etc. Conclusion: These studies suggest that there can be newdevelopmentsfor diagnosis and treatment ofepilepsy patients. Advanced techniquesand miRNA combination may producemore effective rolesin epilepsy and other disease. These reports will be available to solve the useof miRNAs asbiomarkers and novel therapy approaches for epilepsy. To summarize all, researcher who focus on miRNAsshould have information onthe causes, treatment, and diagnosis of epilepsy. exploration of anyof these effects on the efficacy of these drugs is worthwhile.

Epilepsy,epilepsy biomarkers, microRNA, seizures, diagnosis, temporal lobe epilepsy,status epilepticus, epileptogenesis